Dialybrid announces the closing of a €15 million series A round led by new lead investor XGEN Venture, with the participation of CDP Venture Capital (Rilancio Fund). The financing will fund the clinical validation of Dialybrid’s Silkothane® Arteriovenous Graft as a hemodialysis vascular access, and the preclinical development of the proprietary Silkothane® material in other vascular applications. Silkothane® Arteriovenous Graft is a novel hybrid arteriovenous graft engineered to integrate into patients’ vessels and provide a safe, durable, easy-to-cannulate vascular access for hemodialysis in patients with end-stage kidney disease.
Dialybrid secures €15 million series A round




